A key player in this success story is ADI-PEG20, a drug that destroys cancer cells by depriving them of the amino acid arginine. Mesothelioma cells cannot produce their own arginine, making them particularly vulnerable to this targeted therapy.

The ATOMIC-meso study, which included 249 patients, compared the drug with placebo chemotherapy plus chemotherapy. Combination therapy increased median survival by 1.6 months; This is an important development for this rapidly progressing cancer. More importantly, the four-year survival rate quadrupled with the new treatment, giving patients additional hope.

This is the first successful combination of chemotherapy with a drug targeting cancer metabolism in mesothelioma in two decades. The study paves the way for further investigation of the potential of ADI-PEG20 in other arginine-dependent cancers such as sarcoma and glioblastoma multiforme.

News materials cannot be equated with a doctor’s prescription. Consult an expert before making a decision.

Source: Ferra

Previous articleRyzen 7 8700G: See price and benchmarks of the GTX 1060-beating processor
Next articleThe evolution of the Google Pixel processor: From saying goodbye to Snapdragon to the future of TensorPhones 22:30 | February 18, 2024
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.

LEAVE A REPLY

Please enter your comment!
Please enter your name here